hasMolecularTarget
P37016
predicate
Indicates that one entity (such as a drug or compound) is directed toward, binds to, or specifically interacts with a particular molecular target (such as a protein, receptor, or gene).
All labels observed (28)
| Label | Occurrences |
|---|---|
| targetOfDrug | 48 |
| hasMolecularTarget canonical | 28 |
| therapeuticTargetOf | 15 |
| isTargetOfDrug | 14 |
| drugTarget | 13 |
| hasPharmacologicTarget | 5 |
| isDrugTargetFor | 5 |
| isDrugTargetOf | 5 |
| isTherapeuticTargetOf | 5 |
| targetMolecule | 5 |
| drugTargetFor | 4 |
| molecularTarget | 4 |
| affectsMolecularTarget | 3 |
| hasMolecularTargetClass | 3 |
| hasMolecularTargetType | 3 |
| targetsEnzyme | 3 |
| isTargetOfDrugClass | 2 |
| ligandOf | 2 |
| targetsDrug | 2 |
| targetsMolecule | 2 |
| therapeuticTarget | 2 |
| biologicTarget | 1 |
| drugMechanismStudied | 1 |
| hasPharmacologicalTargetCell | 1 |
| hasPrimaryMolecularTarget | 1 |
| molecularTargetClass | 1 |
| pertuzumabTarget | 1 |
| trastuzumabTarget | 1 |
Description generation (PDg)
The one-sentence description above was generated by prompting gpt-5.1 with the predicate name and this instruction.
Instruction
Given a predicate that represents a relationship or action between entities, generate a one-sentence description explaining its meaning. # Instructions Focus on describing the relationship, not the entities themselves. # Response Format Begin the description with \' Indicates...\'
Input
Predicate: hasMolecularTarget
Generated description
Indicates that one entity (such as a drug or compound) is directed toward, binds to, or specifically interacts with a particular molecular target (such as a protein, receptor, or gene).
Sample triples (180)
| Subject | Object |
|---|---|
|
MAGL enzyme
surface form:
MAGL
|
analgesic agents via predicate surface "drugTargetFor" ⓘ |
|
MAGL enzyme
surface form:
MAGL
|
anti-inflammatory agents via predicate surface "drugTargetFor" ⓘ |
|
MAGL enzyme
surface form:
MAGL
|
neuroprotective agents via predicate surface "drugTargetFor" ⓘ |
|
MAGL enzyme
surface form:
MAGL
|
anticancer agents via predicate surface "drugTargetFor" ⓘ |
| pirtobrutinib | tyrosine kinase via predicate surface "hasMolecularTargetClass" ⓘ |
| EGFR | gefitinib via predicate surface "targetOfDrug" NERFINISHED ⓘ |
| EGFR | erlotinib via predicate surface "targetOfDrug" NERFINISHED ⓘ |
| EGFR | afatinib via predicate surface "targetOfDrug" NERFINISHED ⓘ |
| EGFR | osimertinib via predicate surface "targetOfDrug" NERFINISHED ⓘ |
| EGFR | dacomitinib via predicate surface "targetOfDrug" NERFINISHED ⓘ |
| EGFR | cetuximab via predicate surface "targetOfDrug" ⓘ |
| EGFR | panitumumab via predicate surface "targetOfDrug" NERFINISHED ⓘ |
| EGFR | necitumumab via predicate surface "targetOfDrug" NERFINISHED ⓘ |
| fam-trastuzumab deruxtecan | ERBB2 NERFINISHED ⓘ |
|
MS4A1 gene
surface form:
MS4A1
|
rituximab via predicate surface "targetOfDrug" NERFINISHED ⓘ |
|
MS4A1 gene
surface form:
MS4A1
|
ofatumumab via predicate surface "targetOfDrug" NERFINISHED ⓘ |
|
MS4A1 gene
surface form:
MS4A1
|
obinutuzumab via predicate surface "targetOfDrug" NERFINISHED ⓘ |
|
MS4A1 gene
surface form:
MS4A1
|
ocrelizumab via predicate surface "targetOfDrug" ⓘ |
|
MS4A1 gene
surface form:
MS4A1
|
ublituximab via predicate surface "targetOfDrug" NERFINISHED ⓘ |
| BAFF | belimumab via predicate surface "targetOfDrug" ⓘ |
| BAFF | tabalumab via predicate surface "targetOfDrug" NERFINISHED ⓘ |
| BAFF | blisibimod via predicate surface "targetOfDrug" NERFINISHED ⓘ |
| BAFF | atacicept via predicate surface "targetOfDrug" NERFINISHED ⓘ |
| interleukin-4 | dupilumab via predicate surface "isTargetOfDrug" NERFINISHED ⓘ |
| interleukin-4 | pitrakinra via predicate surface "isTargetOfDrug" NERFINISHED ⓘ |
| interleukin-4 | pascolizumab via predicate surface "isTargetOfDrug" NERFINISHED ⓘ |
|
CLinical Evaluation Of Pertuzumab And TRAstuzumab
surface form:
CLEOPATRA trial
|
HER2 via predicate surface "targetMolecule" NERFINISHED ⓘ |
|
CLinical Evaluation Of Pertuzumab And TRAstuzumab
surface form:
CLEOPATRA trial
|
HER2 dimerization domain via predicate surface "pertuzumabTarget" ⓘ |
|
CLinical Evaluation Of Pertuzumab And TRAstuzumab
surface form:
CLEOPATRA trial
|
HER2 extracellular domain via predicate surface "trastuzumabTarget" NERFINISHED ⓘ |
| Corynebacterium diphtheriae | elongation factor 2 via predicate surface "targetMolecule" ⓘ |